21 August 2025

Evrysdi ▼ 0.75 mg/mL powder for oral solution (risdiplam): omission of mandatory labelling statement in the EU product label and summary of product characteristics

Dear Healthcare Professional,

Roche Products (Ireland) Limited in agreement with the European Medicines Agency and the Malta Medicines Authority would like to inform you of the following:

Summary

- **A mandatory labelling statement has been mistakenly omitted from the EU product label and summary of product characteristics (SmPC) for Evrysdi 0.75mg/mL powder for oral solution.**

- **The statement "*Do not store above 25°C*" is missing from section "6.4 Special precautions for storage" (within the powder for oral solution sub-section) of the SmPC, product carton and bottle labels, and the Instruction for Constitution. The package leaflet is not impacted, as the patients only receive the constituted oral solution, and the proper storage condition for the constituted oral solution is already included in the package leaflet.**

- **Pharmacists must not dispense Evrysdi 0.75 mg/mL powder for oral solution if the storage temperature of the unconstituted powder has exceeded 40°C / 75% RH (relative humidity) for 3 months, or 30°C / 75% RH for 12 months because the impact of storing outside of these conditions has not been studied.**

- **Please submit a product complaint 24/7 to Ireland Quality at Roche Products (Ireland) Limited by email (ireland.quality.iq1@roche.com) to receive advice about replacement and ensuring continued dosing.**

Background

Evrysdi (risdiplam) is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi powder for oral solution must be constituted with purified water or water for injection by a healthcare professional (e.g. pharmacist) prior to being dispensed.

On May 21, 2025, a misalignment was identified between the approved product labelling statement and the storage conditions in Roche's internal labelling statement database for Evrysdi when it is stored as a powder (not after it is constituted with water). The internal database, regarding the unconstituted powder, states "do not store above 25°C," while the documentation for the marketing authorisation and actual product labelling for EU/EEA

countries does not include this temperature-specific storage statement. This issue affects all EU/EEA countries.

Testing indicates that Evrysdi in the powder form is stable at 25°C / 60% RH (relative humidity) during the full shelf-life of the product. All available stability data collected at 40°C / 75% RH for 3 months, at 30°C / 75% RH for 12 months, and 25°C / 60% RH (full shelf life) demonstrate that Evrysdi in the powder state remains within specifications under these conditions, allowing for temperature excursions of up to 30°C or even 40°C for several months. A decrease in risdiplam content was observed at 40°C / 75% RH over 6 months with the content found to be at 94.7% (limit: 95.0%). This lowered content is not expected to cause concerns with potential underdosing.

Transport of the medicinal product to local wholesalers or pharmacies is maintained at 2 - 25°C.

Based on the stability data mentioned above, an impact on patient safety is not expected, if Evrysdi is stored within these parameters.

Corrective and Preventive Actions

The EU SmPC, labelling and instruction for constitution will be updated with the relevant storage conditions for the powder form of Evrysdi. The label update will be expedited. Corrective and preventive actions have been defined to rectify the situation as soon as possible and to prevent similar events from recurring.

Pharmacists should:

- not dispense Evrysdi 0.75mg/ mL Powder for Oral Solution if the storage temperature of the powder exceeded 40°C/ 75% RH for 3 months, or 30°C / 75% RH for 12 months.
- submit a product complaint 24/7 to Ireland Quality at Roche Products (Ireland) Limited by email (ireland.quality.iq1@roche.com) to receive advice about replacement and ensuring continued dosing.

Call for reporting

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form available online at http://www.medicinesauthority.gov.mt/adrportal and sent to Pharmacovigilance Section at Post-Licensing Directorate, Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN or sent by email to: postlicensing.medicinesauthority@gov.mt.

Healthcare professionals may also report any suspected adverse reactions to the Drug Surveillance Centre in Roche Products (Ireland) Limited by telephone [00 353 (1) 469 0700] or email (Ireland.drug_surveillance_centre@roche.com).

Company contact point

Should you have any questions regarding the use of Evrysdi 0.75 mg/mL powder for oral solution (risdiplam) please contact us at: Medical Information at Roche Products (Ireland) Limited by telephone [00 353 (1) 469 0700] or email (Ireland.druginfo@roche.com).

Evrysdi 0.75 mg/mL powder for oral solution Summary of Product Characteristics (SmPC) is available on www.medicines.ie.

Yours sincerely,

Signed by:
Abdul Al Khateeb
Signer Name: Abdul Al Khateeb
Signing Reason: I approve this document
Signing Time: 12-Aug-2025 | 3:57:19 PM CEST
F9CFB425DE454B60AFAF6A34BD82AFFF

Abdul-Hameed Al Khateeb
Country Medical Director

Data Protection Statement
Roche Products (Ireland) Limited ("Roche") process your personal data as part of sending this communication to you. Roche may hold and use personal data provided by you and/or obtained by us and disclose it to other companies in the Roche group, to partners (including other Marketing Authorisation holders), agents and service providers of Roche and governmental agencies and bodies for the purposes of complying with Roche's legal obligations. Your personal data may be transferred outside of the European Economic Area, but any transfers shall be made in accordance with data protection law. You have various rights under data protection law, including the rights to access your personal data and to have any inaccuracies in such data corrected or deleted. Please see our privacy notice on www.roche.ie for further details.